Загрузка...
Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib
Deep molecular response in chronic myeloid leukemia (CML) patients treated with imatinib is a prerequisite for possible discontinuation. We identify clinico-biologic features linked with the probability of reaching MR4.5 (BCR-ABL/ABL ≤ 0.0032% IS) as a stable response (confirmed on two or more conse...
Сохранить в:
| Опубликовано в: : | Oncotarget |
|---|---|
| Главные авторы: | , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Impact Journals LLC
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5800922/ https://ncbi.nlm.nih.gov/pubmed/29484130 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23691 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|